ERBB2 and colorectal carcinoma: CRC shows a frequency of HER2 overexpression ranging between 3 and 5% (in the metastatic setting), while somatic HER2 alterations, including amplifications (in about 5.8%), are found in 7% of patients, as identified in The Cancer Genome Atlas (TCGA) project (Figure 1) [77].